PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced it will release its third quarter 2022 financial results and operational updates on November 9, 2022, prior to the U.S. market opening. The company will host a conference call at 8:30 AM ET to discuss these results. PolyPid focuses on enhancing surgical outcomes through its PLEX technology, deploying drug delivery systems that provide controlled release of pharmaceuticals. Its lead candidate, D-PLEX100, is in Phase 3 trials for infection prevention following surgeries.

Positive

• Scheduled conference call indicates ongoing transparency with investors.
• D-PLEX100 in Phase 3 trials for preventing surgical site infections.

Negative

• None.

PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 9, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, November 9, 2022
Time:	8:30 AM Eastern Time
Conference Call:	https://register.vevent.com/register/BI5e06285152a24249a0330f025cefc01e
Webcast:	https://edge.media-server.com/mmc/p/c6nr79zi

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 

PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

When will PolyPid report Q3 2022 financial results?

PolyPid will report its Q3 2022 financial results on November 9, 2022.

What time is PolyPid's conference call for Q3 2022 results?

The conference call is scheduled for 8:30 AM Eastern Time on November 9, 2022.

What is the focus of PolyPid's lead product candidate D-PLEX100?

D-PLEX100 is focused on preventing surgical site infections and is currently in Phase 3 clinical trials.

How can I access PolyPid's Q3 2022 financial results webcast?

You can access the webcast via the link provided in their press release.